Dual-Target In Vivo CAR-T: Emerging Trends and Competitive Landscape in China Targeting Oncology and Autoimmune Diseases
Legend Biotech
Tumor Cell Immunotherapy Developer
Fosun Pharmaceutical
Healthcare Industry Group
Oricell Therapeutics
Developer of Tumor Immunocyte Products
January 22, 2026
eMedClub News
After the in vivo field gained significant attention through multiple MNC acquisitions, it has ushered in diversified exploration.in vivo CAR-T 、In vivo TCR-T, in vivo TCE, and in vivo CAR-M have all been developed by companies.
Among themThe in vivo CAR-T track has relatively faster progress compared to other in vivo tracks. Notably, with the accumulation and development of technology, it has shown a trend toward evolving into more complex dual-target strategies. Dual-target designs can effectively avoid tumor antigen escape and enhance the specificity of tumor cell killing through synergistic targeting mechanisms. Currently, some companies in China have disclosed relevant layouts.
Legend Biotech
Recently, Legend Biotech announced its business progress at the 44th Annual J.P. Morgan Healthcare Conference, revealing plans to explore highly promising in vivo CAR-Opportunities for T therapies.
Its preclinical data from primates targetsNon-Hodgkin LymphomaTheCD20/CD19 Dual Target in vivo CAR-T Cell TherapyProvided early validation. The candidate pipeline completed the first patient dosing within 6 months after being identified, and it is expected...The first human trial data will begin to be available in the second half of 2026.
At the same time, the company's advanced cell therapy research and development center, located in Philadelphia, Pennsylvania, USA, and covering an area of 31,000 square feet, has been officially launched. It will support the company’s pipeline expansion in the fields of oncology and immunology indications as well as in vivo therapies.Legend BiotechIt also plans to submit multiple IND applications for cancer and autoimmune diseases starting from the second half of 2026.
Fosun Pharmaceutical
On January 13, Fosun Pharmaceutical announced that its subsidiary Fosun Karry had initiated the development of a dual-target in vivo CAR-T product.This product is Fosun Karry's first in vivo CAR-T, covering the field of autoimmune diseases.Field, including refractory diseases such as systemic lupus erythematosus and myasthenia gravis.
This product is based on the introduction of relevant technologies from Tianzeyun Technology and self-developed. The two parties reached an agreement in December 2025, and Fosun Karry obtained Tianzeyun Technology.Antibody-Conjugated LNP, Ionizable LipidsThe licensed rights to two core technologies encompass the research, development, production, and commercialization rights for corresponding in-house projects within the licensed region and field.
According to Fosun Karry's disclosure,Dual-targetIn Vivo CAR-T HasThe advantages of efficiently clearing B cells, controlling symptoms and achieving long-term remission, with high accessibility and superior safety.
Qrigincell Therapeutics
On January 12, Oricell Therapeutics announced the completion of a US$70 million Series C1 financing round. The proceeds will continue to focus on advancing the company’s core pipeline globally, including clinical development of in vivo products and cutting-edge technology research.
It is reported that,The dual-target in vivo CAR-T product independently developed by the company has initiated exploratory clinical research., verifying the technical potential of "off-the-shelf CAR-T" – generating CAR-T cells directly within the patient’s body, significantly improving the accessibility of cellular therapies.
Literature Report
In addition, there are also literature reports on the development of dual-target in vivo CAR-T. In an article titled "T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles," the research team developed targeted lipid nanoparticles.（tLNPs）The NCtx platform has achieved non-viral DNA delivery, and in combination with the SB100x transposase system, it enables the direct in vivo generation of a dual-targeting strategy CAR-T against CD7 and CD3.
Summary
In summary,in vivo CAR-T Driven by both technological accumulation and industrial enthusiasm, the赛道 (track) is evolving towards a dual-target strategy. In China, enterprises and academic research are making joint efforts. Companies like Legend Biotech, Fosun Pharmaceutical, and Oricell Therapeutics, with their differentiated technical approaches and pipeline layouts, are progressively exploring from cancer to autoimmune diseases.More Possibilities for in vivo CAR-T.
Exciting Events
Press and hold to scan the QR code and participate immediately ↓
DianDian "Share”、“Like"and"In Progress”
Give me a little charge~